Study Group 2 (n = 27) Control Group 2 (n=13)
p-value
Control Group 3 (n=8)
p-value
Age at diagnosed (years)
≤49 years 17 (63.0%) 4 (30.8%) 0.056 5 (62.5%) 0.981
>49 years 10 (37.0%) 9 (69.2%) 3 (37.5%)
BRCA-germline-mutation status
BRCA1 mutation 18 (66.7%) 10 (76.9%) 0.687 6 (75.0%) 0.817
BRCA2 mutation 8 (29.6%) 3 (23.1%) 2 (25.0%)
BRCA1 and 2 mutations 1 (3.7%) 0 (0.0%) 0 (0.0%)
NAC-IDS
Yes 5 (18.5%) 5 (38.5%) 0.173 0 (0.0%) 0.189
No 22 (81.5%) 8 (61.5%) 8 (100.0%)
FIGO stage at diagnosed
I/II 4 (14.8%) 2 (15.4%) 0.962 2 (25.0%) 0.502
III/IV 23 (85.2%) 11 (84.6%) 6 (75.0%)
Primary tumor location
Ovary 26 (96.3%) 13 (100.0%) 0.482 7 (87.5%) 0.347
Fallopian tube 1 (3.7%) 0 (0.0%) 1 (12.5%)
Histologic type
High-grade serous 26 (96.3%) 12 (92.3%) 6 (75.0%)
Serous not specified 0 (0.0%) 0 (0.0%) 2 (25.0%)
Endometrioid 1 (3.7%) 0 (0.0%) 0 (0.0%)
Clear-cell 0 (0.0%) 1 (7.7%) 0 (0.0%)
Residual lesions
No 15 (55.6%) 8 (61.5%) 0.932 5 (62.5%) 0.890
Yes 8 (29.6%) 4 (30.8%) 3 (37.5%)
Unknown a 4 (14.8%) 1 (7.7%) 0 (0.0%)
PFI after 1st line of platinum-containing chemotherapy
5-6months 2 (7.4%) 0 (0.0%) 0.222 0 (0.0%) 0.547
≥6, <12 months 6 (22.2%) 6 (46.2%) 3 (37.5%)
≥12 months 19 (70.4%) 7 (53.8%) 5 (62.5%)
PFI after 2nd line of platinum-containing chemotherapy
≥6, <12 months 20 (74.1%) 8 (61.5%) 0.418 5 (62.5%) 0.525
≥12 months 7 (25.9%) 5 (38.5%) 3 (37.5%)
PFI before fourth-line chemotherapy
<6 months 0(0.0%) 0(0.0%) 8(100.0%) 0.000**
≥6, <12 months 1(3.7%) 11(84.6%) 0(0.0%)
≥12 months 26 (96.3%) 2(15.4%) 0(0.0%)